Xenetic Biosciences Total Assets Growth & History (XBIO)
Xenetic Biosciences's total assets was $8.4M for fiscal 2025.
View full Xenetic Biosciences company overviewXenetic Biosciences annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.4M | $1.5M | +21.19% |
| 2024 | 2024-12-31 | $6.9M | −$3.7M | −34.92% |
| 2023 | 2023-12-31 | $10.6M | −$4.1M | −27.96% |
| 2022 | 2022-12-31 | $14.7M | −$5.1M | −25.71% |
| 2021 | 2021-12-31 | $19.8M | $6.6M | +50.35% |
| 2020 | 2020-12-31 | $13.2M | −$8.4M | −38.83% |
| 2019 | 2019-12-31 | $21.5M | $7.1M | +49.31% |
| 2018 | 2018-12-31 | $14.4M | −$4.7M | −24.70% |
| 2017 | 2017-12-31 | $19.2M | −$1.8M | −8.63% |
| 2016 | 2016-12-31 | $21.0M | $4.1M | +24.04% |
| 2015 | 2015-12-31 | $16.9M | $592,242 | +3.63% |
| 2014 | 2014-12-31 | $16.3M | −$3.1M | −16.18% |
| 2013 · Dec 31 | 2013-12-31 | $19.5M | −$5.9M | −23.28% |
| 2013 · Aug 31 | 2013-08-31 | $486,809 | $162,677 | +50.19% |
| 2012 · Dec 31 | 2012-12-31 | $25.4M | — | — |
| 2012 · Aug 31 | 2012-08-31 | $324,132 | — | — |
Xenetic Biosciences quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.0M | $1.6M | +30.15% |
| Q1 2026 | 2026-03-31 | $7.9M | $2.1M | +36.57% |
| Q4 2025 | 2025-12-31 | $8.4M | $1.5M | +21.19% |
| Q3 2025 | 2025-09-30 | $5.1M | −$3.0M | −37.01% |
| Q2 2025 | 2025-06-30 | $5.4M | −$3.7M | −40.73% |
| Q1 2025 | 2025-03-31 | $5.8M | −$3.6M | −38.35% |
| Q4 2024 | 2024-12-31 | $6.9M | −$3.7M | −34.92% |
| Q3 2024 | 2024-09-30 | $8.0M | −$3.9M | −32.73% |
| Q2 2024 | 2024-06-30 | $9.0M | −$3.7M | −29.15% |
| Q1 2024 | 2024-03-31 | $9.4M | −$4.3M | −31.51% |
| Q4 2023 | 2023-12-31 | $10.6M | −$4.1M | −27.96% |
| Q3 2023 | 2023-09-30 | $12.0M | −$3.6M | −23.19% |
| Q2 2023 | 2023-06-30 | $12.7M | −$3.7M | −22.58% |
| Q1 2023 | 2023-03-31 | $13.7M | −$4.3M | −23.73% |
| Q4 2022 | 2022-12-31 | $14.7M | −$5.1M | −25.71% |
| Q3 2022 | 2022-09-30 | $15.6M | −$5.7M | −26.84% |
| Q2 2022 | 2022-06-30 | $16.5M | $5.6M | +50.87% |
| Q1 2022 | 2022-03-31 | $18.0M | $6.2M | +52.90% |
| Q4 2021 | 2021-12-31 | $19.8M | $6.6M | +50.35% |
| Q3 2021 | 2021-09-30 | $21.3M | $12.6M | +144.76% |
| Q2 2021 | 2021-06-30 | $10.9M | −$8.1M | −42.74% |
| Q1 2021 | 2021-03-31 | $11.8M | −$8.9M | −42.97% |
| Q4 2020 | 2020-12-31 | $13.2M | −$8.4M | −38.83% |
| Q3 2020 | 2020-09-30 | $8.7M | −$14.2M | −61.98% |
| Q2 2020 | 2020-06-30 | $19.1M | $3.4M | +21.94% |
| Q1 2020 | 2020-03-31 | $20.6M | $4.2M | +25.33% |
| Q4 2019 | 2019-12-31 | $21.5M | $7.1M | +49.31% |
| Q3 2019 | 2019-09-30 | $22.9M | $7.3M | +47.26% |
| Q2 2019 | 2019-06-30 | $15.6M | −$1.6M | −9.41% |
| Q1 2019 | 2019-03-31 | $16.5M | −$1.1M | −6.20% |
| Q4 2018 | 2018-12-31 | $14.4M | −$4.7M | −24.70% |
| Q3 2018 | 2018-09-30 | $15.5M | $894,057 | +6.11% |
| Q2 2018 | 2018-06-30 | $17.3M | $818,709 | +4.98% |
| Q1 2018 | 2018-03-31 | $17.5M | −$1.3M | −6.84% |
| Q4 2017 | 2017-12-31 | $19.2M | −$1.8M | −8.63% |
| Q3 2017 | 2017-09-30 | $14.6M | $773,598 | +5.58% |
| Q2 2017 | 2017-06-30 | $16.4M | $3.3M | +24.91% |
| Q1 2017 | 2017-03-31 | $18.8M | $471,440 | +2.57% |
| Q4 2016 | 2016-12-31 | $21.0M | $4.1M | +24.04% |
| Q3 2016 | 2016-09-30 | $13.9M | −$387,798 | −2.72% |
| Q2 2016 | 2016-06-30 | $13.2M | −$109,013 | −0.82% |
| Q1 2016 | 2016-03-31 | $18.4M | $4.3M | +30.76% |
| Q4 2015 | 2015-12-31 | $16.9M | $592,242 | +3.63% |
| Q3 2015 | 2015-09-30 | $14.3M | −$5.1M | −26.21% |
| Q2 2015 | 2015-06-30 | $13.3M | −$9.8M | −42.44% |
| Q1 2015 | 2015-03-31 | $14.0M | −$11.8M | −45.72% |
| Q4 2014 | 2014-12-31 | $16.3M | −$3.1M | −16.18% |
| Q3 2014 | 2014-09-30 | $19.3M | — | — |
| Q2 2014 | 2014-06-30 | $23.1M | — | — |
| Q1 2014 · Mar 31 | 2014-03-31 | $25.9M | — | — |
| Q4 2013 · Dec 31 | 2013-12-31 | $19.5M | −$5.9M | −23.28% |
| Q1 2014 · Nov 30 | 2013-11-30 | $448,987 | $97,204 | +27.63% |
| Q4 2013 · Aug 31 | 2013-08-31 | $486,809 | $162,677 | +50.19% |
| Q2 2013 | 2013-05-31 | $277,431 | −$26,425 | −8.70% |
| Q1 2013 · Feb 28 | 2013-02-28 | $270,738 | $19,699 | +7.85% |
| Q4 2012 · Dec 31 | 2012-12-31 | $25.4M | — | — |
| Q1 2013 · Nov 30 | 2012-11-30 | $351,783 | — | — |
| Q4 2012 · Aug 31 | 2012-08-31 | $324,132 | $101,632 | +45.68% |
| Q3 2012 | 2012-05-31 | $303,856 | — | — |
| Q2 2012 | 2012-02-29 | $251,039 | — | — |
| As of Aug 31, 2011 | 2011-08-31 | $222,500 | — | — |
Xenetic Biosciences total assets trends
Over the last five fiscal years, Xenetic Biosciences's total assets decreased from $13.2M to $8.4M, a change of −$4.8M. The latest reported quarter, Q2 2026, shows $7.0M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xenetic Biosciences source filings ↗